Clinical Trials Logo

Neurocognitive Disorders clinical trials

View clinical trials related to Neurocognitive Disorders.

Filter by:

NCT ID: NCT04573985 Completed - Clinical trials for Family Caregiver of Patient With Alzheimer Disease

Impact of the Eurékoi Serious Game on Family Caregivers of Patients With a Major Neurocognitive Disorder

Start date: December 8, 2020
Phase: N/A
Study type: Interventional

This study aims to assess the effectiveness of serious EUREKOI gambling on the anxiety of family caregivers of patients with newly diagnosed Alzheimer's disease.

NCT ID: NCT04529265 Completed - Clinical trials for Postoperative Delirium

Methylene Blue and Postoperative Neurocognitive Disorders

Start date: May 1, 2021
Phase: N/A
Study type: Interventional

Postoperative Neurocognitive Disorders are the most common neurological complications after major surgery, which are associated with higher increased mortality and morbidity in elderly patients undergoing major surgery. Until now highly effective intervention has not been established yet. Recent preclinical studies suggest mithochiondrial dysfunction may be linked to pathogensis of (postoperative delirium) POD and postoperative cognitive dysfunction (POCD). As Methylene blue(MB) is a mitochondrial protective agent and a safe drug with long history of clinical use, we propose that mitochondrial-targeted interventions may be useful to prevent POD/POCD in surgical patients.

NCT ID: NCT04417751 Completed - Dementia Clinical Trials

Care at 360º: A Long-term Individual Cognitive Stimulation Program

Start date: July 1, 2020
Phase: N/A
Study type: Interventional

The aim of the intervention proposed in the present study is to assess the effect of a cognitive stimulation (CS) intervention program in an individual and long-term format, for non-institutionalized elderly people with neurocognitive disorders and in a situation of social vulnerability. Specifically, to test the effectiveness of CS on the global cognitive state, on mood state, on quality of life and on functional state. The program will be composed by 50 sessions, including three of assessment sessions (pre, intra and post-intervention). Each session will have a duration of 45 minutes with a weekly frequency. Control group participants will maintain their treatment as usual.

NCT ID: NCT04266002 Completed - HIV-1-infection Clinical Trials

HIV-1 Infected Adult Subjects With HIV-associated Neurocognitive Disorders Despite Effective Antiretroviral Therapy

Start date: November 1, 2011
Phase: N/A
Study type: Interventional

Prospective study in HIV-1 infected adult subjects with HIV-associated neurocognitive disorders despite effective antiretroviral therapy in plasma for more than one year, analyzing the evolution of cognitive disorders and markers of macrophagic inflammation in blood and cerebrospinal fluid, after a change in HIV treatment with an increased of the new scale CHARTER score ≥ 3 (total treatment score to be ≥ 9)

NCT ID: NCT04210713 Completed - Inflammation Clinical Trials

Neuroimmune Dysfunction in Alcohol Use Disorder

Start date: February 3, 2020
Phase: Phase 1
Study type: Interventional

The objective of this proposal is to advance medication development for alcohol use disorder by examining the efficacy and mechanisms of action of minocycline, a neuroimmune modulator, as a potential treatment. This study has important clinical implications, as the available treatments for alcohol use disorder are only modestly effective and testing novel medications is a high research priority.

NCT ID: NCT04180683 Completed - Depression Clinical Trials

Comparison Study of the Different Abbreviated Versions of the Geriatric Depression Scale

Start date: March 1, 2020
Phase:
Study type: Observational

This multicenter study conducted in several Portuguese institutions aims to compare the screening ability of the several Geriatric Depression Scale (GDS) validated versions for the Portuguese population (GDS-30, GDS-15, GDS-10 and GDS-5), as well as to establish their psychometric properties, using a large sample of elderly people with neurocognitive disorders attending social responses addressed to the elderly. Secondarily, cognitive state will be assessed.

NCT ID: NCT04175223 Completed - HIV Clinical Trials

Impact of Probiotics in HIV-positive Patients With Neurocognitive Disorders

PROCOG
Start date: September 19, 2019
Phase: N/A
Study type: Interventional

The prevalence of HIV-associated neurocognitive disorders (Human Immunodeficiency Virus) remains high during the era of effective triple therapy. The main clinical phenotypes of cognitive impairment are currently represented by asymptomatic neurocognitive neurocognitive impairment (ANI) and mild neurocognitive disorders (MND). In contrast, HIV-associated dementia has almost disappeared. Among the hypotheses to explain the persistence of such a high prevalence is the persistent activation of the immune system despite virological success. This chronic immune activation is believed to be responsible for an inflammatory response and therefore for accelerated cell aging. Several organ complications in HIV-positive patients have been associated with high markers of immune activation. Among the causes of chronic immune activation in virologically controlled patients, an imbalance in the intestinal flora is suspected. In fact, shortly after HIV infection, the virus causes significant apoptosis of intestinal lymphocytes, responsible for a loss of integrity of the intestinal barrier and an imbalance of flora, defined as "dysbiosis". Loss of epithelial integrity and intestinal dysbiosis are suspected of causing systemic passage of bacterial fragments, of which lypopolisaccharide is best known, resulting in chronic activation of the immune system. Several studies suggest a link between digestive bacterial translocation and HIV-related neurocognitive disorders. An improvement in intestinal dysbiosis could therefore contribute to reducing immune activation and the severity of cognitive impairment. A recent study showed that probiotics can reduce levels of neopterin, a marker of monocytic activation, in the cerebrospinal fluid of HIV-positive patients without neurological symptoms. Our objective is to evaluate the impact of probiotic supplementation on immune activation and cognitive performance in virologically controlled HIV-positive patients with a diagnosis of ANI or MND. The potential improvement of cognition through probiotic treatment could therefore improve their quality of life at a lower cost than a drug and without the risk of serious side effects.

NCT ID: NCT04168268 Completed - Delirium Clinical Trials

Patient-reported Outcome Measures After Post-anesthesia Care Unit Delirium

Start date: November 28, 2017
Phase:
Study type: Observational

To assess self-reported cognitive function and health-related quality of life in patients with and without early postoperative delirium

NCT ID: NCT04157244 Completed - Alzheimer Disease Clinical Trials

The Music, Sleep and Dementia Study

Start date: March 12, 2019
Phase: N/A
Study type: Interventional

The specific aims of this studyare to examine the 1) feasibility; 2) acceptability; and 3) preliminary efficacy of a tailored music intervention in home-dwelling older adults with dementia suffering from sleep disruption. Sixty dyads (older adults with dementia and their caregivers) will be randomized to receive the tailored music intervention immediately or following a four week delay.

NCT ID: NCT04142801 Completed - Clinical trials for Neurocognitive Disorders

Efficacy of the Memory Motivation (MEMO) Web Application Training

MeMo
Start date: May 5, 2017
Phase: N/A
Study type: Interventional

Memory, attentional, and behavioural symptoms are the clinical hallmarks of Neurocognitive disorders (NCD) such as Alzheimer's disease and related disorders. The World Health Organisation (WHO) guidelines for risk reduction of cognitive decline and dementia indicate that Cognitive training may be offered to older adults with normal cognition and with mild cognitive impairment to reduce the risk of cognitive decline and/or dementia. The use of Information and Communication Technologies (ICT) in the health domain is progressively expanding. The Alzheimer Innovation Association have developed MeMo (Memory Motivation) a free web application that can be used at home by patients. The objective of the present study was to assess the effectiveness of employing the MeMo platform on cognitive performance in patients suffering from NCD.